Business Context and Reporting Period
Envoy Medical, Inc. (COCH) filed a Form 8-K on August 27, 2024, reporting the entry into a material definitive agreement. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
This filing details a new financing arrangement rather than periodic financial performance metrics such as revenue or operating cash flow.
- Instrument: Promissory Note with a maximum principal amount of $10,000,000.
- Lender: GAT Funding, LLC, an entity controlled by Glen Taylor, a board member and controlling stockholder.
- Initial Draw: $5,000,000 drawn at the initial closing.
- Interest Rate: 8.0% per annum.
- Term: Five years, maturing on August 27, 2029.
- Warrant Commitment Fee: Issuance of 500,000 warrants to purchase Class A Common Stock at an exercise price of $2.97 per share upon the initial funding.
Material Changes and Terms
The filing represents a material change in the company's capital structure through the addition of debt and equity-linked instruments.
- Drawdown Structure: Funds may be drawn in $2,500,000 tranches subject to certain conditions.
- Interest Payment Schedule: Interest accrues but is not paid for the first two years. It compounds and is added to the principal balance on the first and second anniversaries. Quarterly payments in arrears commence after the second anniversary.
- Prepayment: The company may prepay accrued interest and principal without penalty with 10 days' notice.
- Warrant Terms: Warrants are issued at a rate of 250,000 shares per $2,500,000 funded. The exercise price equals the closing price on the funding date. All warrants terminate on the third anniversary of the initial closing.
Outlook, Risks, and Management Commentary
The filing does not provide specific forward-looking guidance, management commentary on operations, or a discussion of risks beyond the terms of the agreement. The transaction was publicly announced via a press release on August 28, 2024.
Investor Verification Checklist
- Verify the specific conditions required to draw the remaining $5,000,000 tranches.
- Confirm the impact of the 8.0% interest rate and compounding mechanism on future debt service obligations.
- Assess the dilution impact of the 500,000 warrants issued at $2.97 per share and potential future warrant issuances.
- Review the related party nature of the transaction with GAT Funding, LLC, controlled by a board member.